Protein Sciences announced that the Food and Drug Administration (FDA) has approved two strain changes of Flublok (trivalent recombinant hemagglutinin [rHA] influenza vaccine) for the 2015/16 flu season.
Flublok is the only influenza vaccine made in a 100% egg-free system and is the first recombinant protein-based vaccine for the prevention of seasonal influenza disease. It is highly purified and contains no preservatives, egg proteins, gelatin, or latex; it also contains three times more antigen than traditional flu vaccines.
Flublok is currently indicated for active immunization against influenza virus subtypes A and B in adults aged ≥18 and is supplied as 0.5mL single-dose vials in 10-count cartons. It is anticipated to be available to distributors and retailers in mid-August.
For more information call (888) 855-7871 or visit Flublok.com.